Monitoring Chronic Myeloid Leukemia: How Molecular Tools May Drive Therapeutic Approaches

More than 15 years ago, imatinib entered into the clinical practice as a “magic bullet”; from that point on, the prognosis of patients affected by chronic myeloid leukemia (CML) became comparable to that of aged-matched healthy subjects. The aims of treatment with tyrosine kinase inhibitors (TKIs) a...

Descripción completa

Detalles Bibliográficos
Autores principales: Izzo, Barbara, Gottardi, Enrico Marco, Errichiello, Santa, Daraio, Filomena, Baratè, Claudia, Galimberti, Sara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6742705/
https://www.ncbi.nlm.nih.gov/pubmed/31555590
http://dx.doi.org/10.3389/fonc.2019.00833

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6742705/
https://www.ncbi.nlm.nih.gov/pubmed/31555590
http://dx.doi.org/10.3389/fonc.2019.00833

Ejemplares similares